866-997-4948(US-Canada Toll Free)

Taxotere (Head and Neck Cancer) Analysis and Forecasts to 2017

Published By :

GlobalData

Published Date : Oct 2011

Category :

Head and Neck Cancer

No. of Pages : 36 Pages


Summary

GlobalDatas pharmaceuticals report, Taxotere (Head and Neck cancer)- Analysis and Forecasts to 2017 provides Taxotere sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxotere including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxotere including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2017 for Taxotere in each of the seven major markets

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer (HNC) Market 4
2.2 Epidemiology 4
2.3 Etiology 8
2.4 GlobalData Analysis and Forecasts Report Guidance 9


3 Head and Neck Cancer Disease: Market Characterization 10
3.1 Head and Neck Cancer Disease Market 10
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 10
3.3 Drivers for the Head and Neck Cancer Disease Market 11
3.3.1 High Incidence 11
3.3.2 High Mortality 12
3.3.3 High Prevalence 12
3.3.4 Low Initial Diagnosis Rate 12


4 Tumor Node Metastases (TNM) Classification of Head and Neck Cancer 13


5 Taxotere 21
5.1 Introduction 21
5.2 Mechanism of Action 21
5.3 Clinical Studies 21
5.4 Approval History of Taxotere 22
5.5 Factors Affecting Sales of Taxotere 23
5.5.1 Head and Neck Cancer Market 23
5.5.2 Better Efficacy 23
5.5.3 Poor Safety 23
5.5.4 Low Competition 23
5.5.5 Low Annual cost 23
5.5.6 Patent Expiry 23
5.6 Drug Risk Benefit Score 23
5.6.1 Efficacy 24
5.6.2 Safety 24
5.6.3 Compliance 24
5.6.4 Dosing Convenience 24
5.7 Intensity of Competition 24
5.8 Sales forecast 24
5.8.1 Target patient Pool of Taxotere 24
5.8.2 Dosing 25
5.8.3 Market Penetration 25
5.8.4 Annual Cost of Therapy 26
5.8.5 Sales Projections 26


6 Head and Neck Cancer Market: Appendix 32
6.1 Market Definitions 32
6.2 Abbreviations 32
6.3 Research Methodology 32
6.3.1 Coverage 33
6.3.2 Secondary Research 33
6.3.3 Forecasting 33
6.3.4 Number of Patients Approved to take the Drug 34
6.3.5 Net Penetration of Drug 34
6.3.6 Net Annual Dosing 35
6.3.7 Annual Cost of Therapy 35
6.3.8 Primary Research 35
6.3.9 Expert Panels 35
6.4 Contact Us 36
6.5 Disclaimer 36
6.6 Sources 36

List of Table


Table 1: Head and Neck Cancer Incidences and Mortality, 2008-2030 4
Table 2: HNC , Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 10
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Taxotere Approval History 22
Table 6: Drug Risk Benefit Score 24
Table 7: Head and Neck Cancer, the US+EU-5+Japan,Estimated Taxotere Sales ($mn), 20022017 26
Table 8: Head and Neck Cancer, the US, Estimated Taxotere Sales ($mn), 20062015 27
Table 9: Head and Neck Cancer, the UK, Estimated Taxotere Sales ($mn), 20062015 28
Table 10: Head and Neck Cancer, France, Estimated Taxotere Sales ($mn), 20062015 28
Table 11: Head and Neck Cancer, Germany, Estimated Taxotere Sales ($mn), 20062015 29
Table 12: Head and Neck Cancer, Italy, Estimated Taxotere Sales ($mn), 20062015 30
Table 13: Head and Neck Cancer, Spain, Estimated Taxotere Sales ($mn), 20062015 30
Table 14: Head and Neck Cancer, Japan, Estimated Taxotere Sales ($mn), 20022017 31

List of Chart


Figure 1: Top 20 Cancers based on Incidence Global, 2008 5
Figure 2: Top 20 Cancers based on Mortality Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 8
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption, the US, 1976-2006 9
Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 10
Figure 8: Oncology, Global, Estimated Incidence 2008-2030 11
Figure 9: Head and Neck Cancer Incidence, Global, 2008-2030 11
Figure 10: Broad Classification of Head and Neck Cancer 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 19
Figure 17: Drug Model Diagram of Taxotere 25
Figure 18: Head and Neck Cancer, the US+EU-5+Japan,EstimatedTaxotere Sales ($mn), 20022017 26
Figure 19: Head and Neck Cancer, the US, Estimated Taxotere Sales ($mn), 20062015 27
Figure 20: Head and Neck Cancer, the UK, Estimated Taxotere Sales ($mn), 20062015 27
Figure 21: Head and Neck Cancer, France, Estimated Taxotere Sales ($mn), 20062015 28
Figure 22: Head and Neck Cancer, Germany, Estimated Taxotere Sales ($mn), 20062015 28
Figure 23: Head and Neck Cancer, Italy, Estimated Taxotere Sales ($mn), 20062015 29
Figure 24: Head and Neck Cancer, Spain, Estimated Taxotere Sales ($mn), 20062015 30
Figure 25: Head and Neck Cancer, Japan, Estimated Taxotere Sales ($mn), 20022017 30
Figure 26: GlobalData Methodology 32
Figure 27: Drug Model Diagram 34
Figure 28: Patients Approved for the Drug 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *